Latest News
-
May 14th, 2008
Novosom granted US and European patents for RNAi-delivering Smarticles® >> -
April 11th, 2007
Novosom AG acquires exclusive option for CD40-targeted antisense inhibitors from Isis Pharmaceuticals >>
SMARTICLES®
for nucleic acid delivery
See how our technology works >>
SMARTICLES®
The SMARTICLES® Technology:
Enabling Systemic DNA Therapeutics.
The early promise of first generation DNA-based therapeutic approaches like siRNA, antisense or decoys foundered on the difficulty of delivering these nucleic acid therapies. Chemical modification, cationic vectors, modified cationic vectors, viral vectors and other technologies have been tried with limited success so far. novosom's solution has been to develop a pioneering liposomal technology with a fully reversible surface charge: SMARTICLES®.
The SMARTICLES® technology allows the delivery of active substances inside the cell either for topical or systemic applications. What makes them different from standard liposomal delivery technologies is that they have a fully reversible surface charge. This unique characteristic is ideally suited to the delivery of encapsulated nucleic acids from injection, through stable and aggregate-free travel within the bloodstream, across cell boundaries to release the oligonucleotide inside the cell.
SMARTICLES® are an enabler for the use of oligonucleotides in systemic and topical treatments. They have proven to be a safe and versatile technology that, as of March 2006, is available in GMP quality suitable for use in humans. novosom has data with both single stranded and double stranded oligonucleotide technologies in RA, IBD, transplant, liver diseases and xenograft oncology models. In addition, initial GLP toxicity studies have shown very high tolerability of the carrier. The Company has secured SMARTICLES® with a number of patent families that cover the technology, its components and manufacturing.
Click here to see an animation of the process by which SMARTICLES® deliver DNA based therapeutics inside a cell.
Licensing
Novosom is using the SMARTICLES® technology for its own and the technology is also available for licensing. If you are interested in hearing more about this, simply contact us via the details here.